Mitsubishi UFJ Trust & Banking’s Axsome Therapeutics AXSM Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$607K	Buy	+2,480	New	+$538K	﹤0.01%	1003

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's AXSM Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 2,480 shares worth $607K. The stake represents ﹤0.01% of the portfolio and ranks #1003 among its holdings.

504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 2,480 shares of Axsome Therapeutics worth $607K as of Q2 2026.
Axsome Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
Axsome Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1003 holding.
504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.